Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022 CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine...

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for protection against non-invasive pneumococcal pneumonia in...

Blue Water Vaccines to Present at World Vaccine Congress Europe 2022 CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...

Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate...